An oncologist from Atrium Health outlines how saving time administering immunotherapy could have far-reaching benefits.

An expert discusses how the availability of subcutaneous (SC) immune checkpoint inhibitors (ICI) for bladder cancer impacts ...

Subcutaneous nivolumab was approved for multiple indications, including as adjuvant therapy for MIUC by the FDA in 2024, "and may provide an alternative for patients across tumors," he noted.

Opdivo Qvantig (nivolumab and hyaluronidase ... It is the second drug in the PD-1/PD-L1 inhibitor class to be cleared in a subcutaneous injection form by the FDA after Roche's Tecentriq Hybreza ...

BMS said it would discuss the new data with health authorities with a view to filing for approval of subcutaneous nivolumab. All the front-runners in the PD-1/PD-L1 inhibitor category are working ...

In a study of patients with advanced melanoma, the prevalence of cutaneous immune–related adverse events (cirAEs) associated with nivolumab/relatlimab combination therapy was 21.5%, with rash ...

Adjuvant therapy with nivolumab (Opdivo, “nivo”) continues to show disease-free survival (DFS) and overall survival (OS) benefits compared with placebo among patients with muscle-invasive ...

BMY is banking on new drugs to offset generic competition for older drugs. However, this might not be enough as the outlook ...

The CheckMate -816 trial shows nivolumab plus platinum-doublet chemotherapy significantly improves overall survival in resectable non-small cell lung cancer.